JP2010534664A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534664A5
JP2010534664A5 JP2010518314A JP2010518314A JP2010534664A5 JP 2010534664 A5 JP2010534664 A5 JP 2010534664A5 JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010534664 A5 JP2010534664 A5 JP 2010534664A5
Authority
JP
Japan
Prior art keywords
fibrosis
pharmaceutical formulation
drug
protein
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010518314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534664A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070588 external-priority patent/WO2009015063A2/en
Publication of JP2010534664A publication Critical patent/JP2010534664A/ja
Publication of JP2010534664A5 publication Critical patent/JP2010534664A5/ja
Pending legal-status Critical Current

Links

JP2010518314A 2007-07-23 2008-07-21 Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物 Pending JP2010534664A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95127007P 2007-07-23 2007-07-23
US95541407P 2007-08-13 2007-08-13
PCT/US2008/070588 WO2009015063A2 (en) 2007-07-23 2008-07-21 Methods and compositions for treating fibrosis related disorders using il-17 antagonists

Publications (2)

Publication Number Publication Date
JP2010534664A JP2010534664A (ja) 2010-11-11
JP2010534664A5 true JP2010534664A5 (enExample) 2011-08-11

Family

ID=40282097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518314A Pending JP2010534664A (ja) 2007-07-23 2008-07-21 Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物

Country Status (5)

Country Link
US (1) US20110091378A1 (enExample)
EP (1) EP2182943B1 (enExample)
JP (1) JP2010534664A (enExample)
ES (1) ES2614735T3 (enExample)
WO (1) WO2009015063A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
RU2537142C2 (ru) * 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
JP2011032170A (ja) * 2009-07-29 2011-02-17 Morinaga Milk Ind Co Ltd ヒト細胞ｉｌ−１７産生抑制剤
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
US20140044731A1 (en) * 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
HRP20180028T4 (hr) * 2011-03-16 2020-10-02 F. Hoffmann - La Roche Ag Kromatografija izmjene iona s poboljšanom selektivnošću za odvajanje polipeptidnih monomera, agregata i fragmenata modulacijom pokretne faze
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN109796534B (zh) * 2017-11-16 2021-08-10 北京比洋生物技术有限公司 抗il-17抗体/tnfr ecd融合蛋白及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
ES2229264T5 (es) * 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1765865A2 (en) * 2004-06-10 2007-03-28 ZymoGenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
NZ574804A (en) * 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a

Similar Documents

Publication Publication Date Title
US12286432B2 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP2005512522A5 (enExample)
US8993622B2 (en) Antiviral compounds
US6936629B2 (en) Compounds and methods for the treatment or prevention of flavivirus infections
JP2007508011A5 (enExample)
AU2011237421B2 (en) Inverse agonists and neutral antagonists for the TSH receptor
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
CN103420917B (zh) 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用
RU2003131178A (ru) Агонисты никотиновых рецепторов для лечения воспалительных заболеваний
JP2026040489A (ja) 骨髄増殖性新生物の治療のためのリシン特異的ヒストンデメチラーゼ阻害剤
JPWO2003097031A1 (ja) メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤
Huang et al. Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis
CN102088976B (zh) 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN106458920B (zh) 炔基吲唑衍生物及其用途
JP2010511598A5 (enExample)
US9181187B2 (en) Therapeutic agent for urinary excretion disorder
JP2021506975A (ja) 線維症を処置するための化合物および組成物
JPWO2003042194A1 (ja) カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
JPWO2007026737A1 (ja) 関節リウマチの予防及び／又は治療法
HK40128663A (zh) 改善骨骼肌功能的方法
WO2025213190A1 (en) Methods of treating a disease or condition associated with weight gain
EP1941911A1 (en) Method for prevention and/or treatment of rheumatoid arthritis
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof